Clinical trials: Schwannoma, Vestibular
Central Nervous System Tumor
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
The purpose of this study is to examine the use of a single dose of tozuleristide (24 or 36 mg) and the Canvas imaging system during surgical resection of primary central nervous system (CNS) tumors: Primary gadolinium enhancing…
- Trial name
- NCT04743310
- Testing
- tozuleristide, Canvas imaging system, Surgical resection of tumor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- John Yu
Neurofibromatosis
Natural History Study of Patients With Neurofibromatosis Type 2
Objective With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2.
- Trial name
- NCT00598351
- Where
- United States
- Volunteers
- 269 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Vestibular Schwannoma
Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function
The purpose of the study is to determine whether vestibular and postural compensation following schwannoma surgery is improved by ablating remaining vestibular function prior to surgery, through gentamicin injections in the…
- Trial name
- NCT02379754
- Testing
- Gentamicins
- Where
- Sweden
- Sponsor
- Lund University
Brain Tumor, Recurrent, Vestibular Schwannoma
Vegetative Monitoring During Brainstem-associated Surgery
Intraoperative Monitoring of Heart rate variability, Blood pressure variability, Baroreceptorsensivity etc.
- Conditions
- Brain Tumor, Recurrent, Vestibular Schwannoma, Brainstem Neoplasm, Brainstem Glioma
- Trial name
- NCT03666507
- Testing
- Intraoperative Monitoring during resection of brain tumor
- Where
- Germany
- Volunteers
- 103 people
- Sponsor
- University Hospital Tuebingen
Vestibular Schwannoma, Meningioma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
This will be a multi-center, proof of concept phase 0 study to assess the suppression of p-AKT in Vestibular Schwannoma (VS) and meningiomas by AR-42 in adult patients undergoing tumor resection.
- Conditions
- Vestibular Schwannoma, Meningioma, Acoustic Neuroma, Neurofibromatosis Type 2
- Trial name
- NCT02282917
- Testing
- AR-42
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Vestibular Schwannoma, Unilateral Vestibular Deficit
Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular Schwannoma
The goal of this clinical trial is to visualize the possible activation of vestibular centers in the brain using in patiens with unilateral vestibular damage, specifically in patients after vestibular schwannoma surgery.
- Conditions
- Vestibular Schwannoma, Unilateral Vestibular Deficit, Healthy
- Trial name
- NCT07130851
- Testing
- vestibular schwannoma resection
- Where
- Czechia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Marketa Bonaventurova
Neurofibromatosis 2
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
OBJECTIVES: I. Define the tonotopocity of multichannel brain stem stimulation and use this information to better program the auditory brain stem implant for an individual. II.
- Trial name
- NCT00004437
- Testing
- Multichannel Auditory Brain Stem Implant
- Sponsor
- FDA Office of Orphan Products Development
Vestibular Schwannoma
Vestibular Outcomes in Vestibular Schwannoma
Previous studies have shown that vertigo is the symptoms that mostly affect quality of life in patients with vestibular schwannoma.
- Trial name
- VOVS (NCT03346889)
- Where
- Norway
- Volunteers
- 155 people
- Sponsor
- Haukeland University Hospital
Acoustic Neuroma, Labyrinthitis Ossificans
Maintaining Cochlear Patency After VIIIth Nerve Surgery
Tumors arising from the VIIIth Nerve (vestibulo-cochlear nerve) typically present with progressive unilateral hearing loss and tinnitus.
- Conditions
- Acoustic Neuroma, Labyrinthitis Ossificans, Profound Hearing Impairment
- Trial name
- NCT03261726
- Testing
- MedEl Test Electrode Placer
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Neuroma, Acoustic
Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy
The investigators study is to investigate safety and efficacy of performing a planned incomplete removal of large acoustic neuroma tumors to decrease surgical morbidity and yet avoid tumor recurrence by post-operative radiation…
- Trial name
- NCT01129687
- Testing
- Microsurgery, Stereotactic radiation therapy
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Stanford University
Patient Operated on From a Vestibular Schwannoma With a Middle Ear Exclusion
Robot Based Tympanic Tube Placement
Middle ear surgery is performed in a deep workspace through a narrow approach to the tympanic cavity, either by the external auditory canal, or by drilling the temporal bone.
- Trial name
- ROBOTOL (NCT03569943)
- Testing
- Robot Based Transtympanic drain placement
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neurofibromatosis Type 2, Vestibular Schwannomas
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
The purpose of this study is to determine if the study drug, AXITINIB, has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2).
- Trial name
- NCT02129647
- Testing
- Axitinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- NYU Langone Health
Vestibular Schwannoma, Acoustic Neuroma
Study of Aspirin in Patients With Vestibular Schwannoma
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
- Conditions
- Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
- Trial name
- NCT03079999
- Testing
- Aspirin
- Where
- 5 sites in United States
- Volunteers
- 97 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Neurofibromatosis Type 2, Vestibular Schwannoma
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults.
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Acoustic Neuroma
- Trial name
- NF2 (NCT03210285)
- Testing
- Whole exome sequencing
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Tuebingen
Vestibular Schwannoma
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
A recent study by Plotkin et al. showed that bevacizumab (Avastin) treatment was followed by clinically meaningful hearing improvement, tumor-volume reduction, or both in some, but not all, patients with Vestibular Schwannoma…
- Trial name
- NCT01083966
- Testing
- Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Vestibular Schwannoma
Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF
Patients undergoing surgery of a vestibular schwannoma will be included in the study. Patients will receive triamcinolone acetonide 24h before surgery.
- Trial name
- NCT04658836
- Testing
- Triamcinolone Acetonide 40mg/mL
- Where
- Austria
- Volunteers
- 21 people
- Sponsor
- Medical University of Vienna
Vestibular Schwannoma
Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI
Endolymphatic hydrops is well known of the lay public in its primary form that is Ménière disease. Nowadays, the best w ay to approach it in vivo, is to use magnetic resonance imaging (MRI).
- Trial name
- NCT03593577
- Where
- France
- Volunteers
- 185 people
- Sponsor
- University Hospital, Strasbourg, France
Neurofibromatosis Type 2, Vestibular Schwannoma
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
This is an adaptive platform-basket trial that aims to evaluate the safety and efficacy of multiple novel agents and combination therapies in patients with NF2-related schwannomatosis (NF2-SWN).
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma
- Trial name
- PRIME-NF2 (NCT07713745)
- Testing
- Selumetinib 25mg/m2, Luvometinib, Serplulimab
- Where
- 5 sites in China
- Volunteers
- 200 people
- Sponsor
- Beijing Tiantan Hospital
Vestibular Schwannoma, Neurofibromatosis Type 2
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
People who have neurofibromatosis type 2 (NF2) can have tumors that grow on the auditory nerves and cause hearing loss. These tumors are called vestibular schwannomas (VSs), or acoustic neuromas.
- Trial name
- NCT01207687
- Testing
- bevacizumab, laboratory biomarker analysis, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Vestibular Schwannoma
Vestibular Schwannoma and Psychological Factors
The surgery of a vestibular schwannoma induces balance disorders which have a an impact on the patient's daily life and disrupt their quality of life.
- Trial name
- NCT01743248
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France